Rosen Law Firm Files Class Action Lawsuit Against Venture Global, Inc. On February 24, 2025, in the Southern District of New York, Rosen Law Firm announced the filing of a class action lawsuit on behalf of purchasers of Venture Global, Inc. (VG) stock. The lawsuit alleges that the company and certain of its top executives…
Levi & Korsinsky Investigates Intellia Therapeutics, Inc. for Potential Securities Law Violations New York, NY – February 4, 2025 Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. (NASDAQ: NTLA) for potential violations of federal securities laws. The investigation follows Intellia’s press release on…
I-Mab’s Exciting Participation in Oppenheimer’s Healthcare Conference: What Does It Mean for You and the World? Last week, I-Mab, a rockstar biotech company based in the land of free and the home of the brave (Rockville, MD), made a big announcement. They’re gearing up to strut their stuff at the Oppenheimer 35th Annual Healthcare Life…
Hedge Funds Bid Adieu to Tech and Media Stocks: What Does This Mean for You and the World? In the whimsical world of finance, where billions of dollars dance around stocks, bonds, and commodities like a cosmic ballet, hedge funds wield a significant baton. These financial powerhouses, with their sophisticated algorithms and deep pockets, can…
KBRA Announces Preliminary Ratings for FREMF Series 2025-K169 and Freddie-Mac SPCs New York, NY — In an exciting development for the mortgage-backed securities (MBS) market, KBRA (Kroll Bond Rating Agency) recently announced the assignment of preliminary ratings to four classes of FREMF Series 2025-K169 mortgage pass-through certificates and three classes of Freddie-Mac structured pass-through certificates…
Regeneron Pharmaceuticals Announces Encouraging Results from CHORD Trial of DB-OTO Gene Therapy for Genetic Hearing Loss Regeneron Pharmaceuticals, a leading biotechnology company, recently released updated data from the Phase 1/2 CHORD (Combining Hearing Restoration and Otoferlin Delivery) trial. This trial involves the investigational gene therapy DB-OTO, designed to treat profound genetic hearing loss caused by…
Sensei Biotherapeutics: John Celebi’s Presentation at Oppenheimer’s Healthcare Conference On February 4, 2025, Sensei Biotherapeutics, Inc., a leading clinical stage biotechnology company specializing in next-generation therapeutics for cancer patients, made an important announcement. The company’s President and Chief Executive Officer, John Celebi, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. The virtual event…
Mesa Laboratories’ Third Quarter Fiscal Results: A Detailed Analysis On February 4, 2025, Mesa Laboratories, Inc. (MLAB), a pioneering company in the design and manufacture of life science tools and critical quality control solutions, reported its financial results for the third quarter of its fiscal year 2025, which ended on December 31, 2024. The following…
